AR
The startup develops a targeted cancer therapy that utilizes biotechnology to specifically attack therapy-resistant cancer cells, thereby preventing tumor recurrence and metastasis. This approach aims to reduce cancer-related mortality by effectively treating aggressive brain cancers and inhibiting the spread of other invasive cancers.
Updated 18 months ago
Funding
$630K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VT
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a targeted cancer therapy that utilizes biotechnology to specifically attack therapy-resistant cancer cells, thereby preventing tumor recurrence and metastasis. This approach aims to reduce cancer-related mortality by effectively treating aggressive brain cancers and inhibiting the spread of other invasive cancers.